Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Partially Observer-Blind, Single-Centre Study to Evaluate Safety and Immunogenicity of MF59-Adjuvanted or Non-Adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine.

Next Previous
Search
Trial Profile

A Randomized, Partially Observer-Blind, Single-Centre Study to Evaluate Safety and Immunogenicity of MF59-Adjuvanted or Non-Adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary) ; MF 59
  • Indications Influenza A virus H5N1 subtype
  • Focus Pharmacodynamics

    • Most Recent Events

    • 24 Jun 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 24 Jun 2012 United Kingdom Clinical Research Network reports accrual to date changed from 76 to 77%.
    • 30 Jul 2011 Planned end date changed from 30 Nov 2010 to 6 Jul 2011 as reported by UKCRN.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top